TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
cancelled
Official procurement procedure

Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)

Financial leasing services
Microscopes
Wales (UKL18)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Swansea University: "Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)". Published status: cancelled. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthoritySwansea UniversityScope & CategoriesNot publishedSubmission Window
cancelled
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Swansea University
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Swansea University. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
2Bids / Report
0% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 1 active published awards; 1 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthoritySwansea University
Procedure methodNot published
Procurement categoryNot published
Statuscancelled
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published8 Mar 2021, 14:48 GMT
Last source update8 Mar 2021, 14:48 GMT
Recurring procurementNot published
ClassificationFinancial leasing services, Microscopes
Delivery area
Wales (UKL18)
OCIDocds-h6vhtk-029974
What is being bought
The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6 million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer. A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
What changed
From the official release history
  1. Status changed to cancelled
    8 Mar 2021, 14:48 GMT
  2. Official notice release published
    8 Mar 2021, 14:48 GMT
  3. Buyer information updated
    8 Mar 2021, 14:48 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    he Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer. A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    8 Mar 2021, 14:48 GMT
  2. Award unsuccessful
    Not published · Not published
Commercial outcome and competition
Awards
Awarded supplier not published
Not published · Not published · unsuccessful
ContractsNo contract published
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

Swansea University

Contracting authority GB-FTS-7944
View buyer profile

  • Swansea University
    buyer
    centralPurchasingBody

    Procurement - Finance, Swansea University, Singleton Park, Swansea, UKL18, SA2 8PP
    procurement@swansea.ac.uk
    +44 1792295890

  • European Union
    funder

  • High Court
    reviewBody

    Royal Courts of Justice, The Strand, London, WC2A 2LL
    +44 2079477501
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleNot published